It's an exciting day at Relief as we announce our agreement with Eton Pharmaceuticals, Inc! Through this partnership, Eton has been granted an exclusive license for the commercialization of our GOLIKE® family of products in the United States. Our collaboration with Eton combines our innovative GOLIKE products with Eton’s valuable experience in the metabolic area. Read more here: https://lnkd.in/diKvRXVU $RLF $RLFTF $RLFTY #phenylketonuria #PKU #businessdevelopment #commercialization #dealnews
RELIEF THERAPEUTICS Holding SA
Biotechnology Research
Providing relief to patients with unmet medical needs in select specialty and rare diseases.
About us
RELIEF THERAPEUTICS Holding SA (SIX: RLF; OTCQB: RLFTF, RLFTY) We are a biopharmaceutical company committed to providing therapeutic relief to patients living with rare diseases. Our goal is to advance treatment paradigms and deliver improvements in efficacy, safety and convenience to benefit the lives of patients and their families. Our therapeutic focus is on rare indications for metabolic disorders, pulmonary diseases, and dermatology/connective tissue disorders.
- Website
-
https://relieftherapeutics.com/
External link for RELIEF THERAPEUTICS Holding SA
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Geneve
- Type
- Public Company
- Founded
- 2013
- Specialties
- Acute Lung Injury, Pulmonary Sarcoidosis, Lung Fibrosis, Acute Respiratory Distress Syndrome, Urea Cycle Disorders, Maple Syrup Urine Disease, Rare Diseases, Epidermolysis Bullosa, Phenylketonuria, PKU, EB, MSUD, UCD, ARDS, Rare Disease, Metabolic Disorders, Acute Lung Disease, and Chronic Lung Disease
Locations
-
Primary
Get directions
Campus Biotech
Geneve, 1202, CH
Employees at RELIEF THERAPEUTICS Holding SA
-
Paolo Galfetti
Chief Operating Officer | Corporate Strategy and Development | M&A | Business Development | Rare Diseases | Pharmaceuticals | Project Management |…
-
Patrizia Marzorati
Strategic Regulatory and Medical Advisor/Global Medical Affairs, PhD, Rare Disease, Orphan drug, Innovation, Pharmaceutical
-
Vincenzo Gallo
Head of Legal and Compliance - Member of the Executive Committee - Corporate Board Secretary
-
Gregory Van Beek
MD @ GEM Global Emerging Markets